Skip to main content
TIBET AIM PHARM. INC. logo

TIBET AIM PHARM. INC. — Investor Relations & Filings

Ticker · 002826 ISIN · CNE100002C39 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,085 across all filing types
Latest filing 2017-11-28 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002826

About TIBET AIM PHARM. INC.

https://www.emyy.cn

Tibet Aim Pharm. Inc. is a pharmaceutical enterprise focused on the research, development, production, and distribution of medicinal products. The company integrates traditional Tibetan medicine with modern pharmaceutical manufacturing processes to develop a diverse portfolio of treatments. Its core product range typically includes cardiovascular medications, digestive system therapies, and specialized herbal formulations derived from high-altitude botanical sources. Tibet Aim Pharm. Inc. emphasizes the modernization of traditional formulas through rigorous clinical testing and standardized production techniques. The company serves healthcare providers and patients by providing therapeutic solutions that bridge ancient medical knowledge with contemporary scientific standards.

Recent filings

Filing Released Lang Actions
独立董事关于应收账款合并报表范围内关联方组合计提坏账准备的会计估计变更的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from independent directors regarding a change in accounting estimates related to bad debt provisions for accounts receivable within consolidated financial statements. It references regulatory guidance from the China Securities Regulatory Commission and company laws. The document is short (566 characters) and primarily contains an attestation or certification by independent directors rather than substantive financial data or a full report. It does not present full financial statements or detailed analysis. Therefore, it fits the criteria for a Regulatory Filing (RNS) as it is a formal regulatory attestation rather than a full audit report or annual/interim report.
2017-11-28 Chinese
第一届监事会第十四次会议决议公告
Regulatory Filings Classification · 90% confidence The document is a resolution announcement from the Supervisory Board (监事会) of 西藏易明西雅医药科技股份有限公司 regarding two main agenda items: a change in accounting estimate related to bad debt provision for accounts receivable within the consolidated financial statements, and a proposal to reapply for a mortgage loan with China Bank. The document includes details of the meeting, voting results, and references to related disclosures on the official information website (巨潮网). The document is relatively short (1613 characters) and does not contain actual financial statements or detailed financial data. It is a formal announcement of board meeting resolutions rather than a full audit report or financial report. It does not fit categories like Annual Report (10-K), Audit Report (AR), or Interim Report (IR). It is not a management change announcement (MANG), nor a call transcript or earnings release. The content is about supervisory board meeting resolutions and approvals, which aligns best with Board/Management Information (MANG) category, as it relates to governance decisions and internal company approvals. However, since it is specifically from the Supervisory Board and concerns meeting resolutions, and no direct management or board member changes are announced, the closest fitting category is Regulatory Filings (RNS) as a fallback for miscellaneous regulatory announcements that do not fit other categories. Given the nature and content, the best classification is Regulatory Filings (RNS) with high confidence.
2017-11-28 Chinese
第一届董事会第二十一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions from the 21st meeting of the first board of directors of the company. It details the meeting's convening, attendance, and the decisions made, including changes in accounting estimates and loan applications. There is no presentation of financial statements or comprehensive financial data, but rather a formal disclosure of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors. The document length is short (1667 characters), and it is not a report or financial statement itself, but a meeting resolution announcement.
2017-11-28 Chinese
关于应收账款合并报表范围内关联方组合计提坏账准备的会计估计变更的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from a company's board regarding a change in accounting estimates related to bad debt provisions for accounts receivable within the consolidated financial statements. It details the nature of the accounting estimate change, the approval process by the board and supervisory committee, and includes independent director opinions. The document does not contain actual financial statements or comprehensive financial data but rather discloses a specific accounting policy change and its rationale. It is not a full annual or interim report, audit report, or earnings release. The document is a regulatory announcement about an accounting estimate change, which fits best under Regulatory Filings (RNS) as it does not meet criteria for other specific report types and is not a report publication announcement due to its substantive content on accounting policy change.
2017-11-28 Chinese
关于持股5%以上股东减持计划的预披露公告特
Major Shareholding Notification Classification · 95% confidence The document is a pre-disclosure announcement regarding a planned shareholding reduction by a shareholder holding more than 5% of the company's shares. It details the shareholder's identity, the number and percentage of shares to be reduced, the reasons for reduction, the method, and compliance with relevant regulations. There are no financial statements, earnings data, or management discussion of financial results. The document is regulatory in nature, focused on shareholding changes by a major shareholder, but it is not a notification of crossing a threshold (which would be MRQ). Instead, it is a planned reduction announcement by a significant shareholder. This fits best under the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels, including planned reductions by shareholders holding more than 5%. The document length is short and it is not an announcement of a report publication or certification. Therefore, the classification is MRQ with high confidence.
2017-11-24 Chinese
关于更换持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for a company related to its IPO process. It includes details about the replacement of a sponsor representative and a brief resume of the new representative. The document is short (800 characters) and does not contain financial statements, earnings data, or detailed report content. It is an announcement about a management or board-related change, specifically about the sponsor representative, which is a senior management role related to IPO supervision. Therefore, it fits best under Board/Management Information (MANG).
2017-10-30 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.